3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Neoplasms
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Melanoma
1
Lung Neoplasms
1
Lung Diseases
1
Liposarcoma
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Advanced Solid Tumors
1
Interventions
sitravatinib
1
Nivolumab
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Metastatic Non-Squamous Non-Small Cell Lung Cancer
×
sitravatinib
×
Clear all
NCT03906071
2025-10-21
SAPPHIRE
Mirati Therapeutics Inc.
Phase 3
Completed
577 enrolled
22 charts